**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

 

**FORM 10-K/A**

**AMENDMENT NO. 1**

 
| **x** | **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF  THE SECURITIES EXCHANGE ACT OF 1934** |
|-------|----------------------------------------------------------------------------------------------------------|

 

**For The Fiscal Year Ended December 31, 2009**

** **

**OR**

 
| **o** | **TRANSITION REPORT PURSUANT TO SECTION 13 OR  15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|-------|--------------------------------------------------------------------------------------------------------------|

 

**For the transition periodfrom                        to                        .**

 

**Commission File No. 0-19700**

 

**AMYLIN PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

 

| **Delaware**                                                     | ** ** | **33-0266089**                        |
|------------------------------------------------------------------|------------|---------------------------------------|
| (State or other jurisdiction of  incorporation or  organization) | ** ** | (I.R.S. Employer

Identification No.) |

 

| **9360 Towne Centre Drive**

**San Diego, California** | ** ** | **92121**  |
|--------------------------------------------------------|------------|------------|
| (Address of principal  executive offices)              | ** ** | (Zip Code) |

 

Registrant’s telephone number, including area code:**(858) 552-2200**

 

Securities registered pursuant to Section 12(b) ofthe Act:

 

| **Title of Each Class** | ** ** | **Name of each Exchange on Which Registered** |
|----------------------------------------|------------|-----------------------------------------------------------------------------|
| Common Stock, $.001 par value          |       | The NASDAQ Stock Market, LLC                                           |

 

Securities registered pursuant to Section 12(g) ofthe Act:

 

**NONE**

(Title of Class)

 

Indicate by check mark ifthe registrant is a well-known seasoned issuer, as defined in Rule 405 of theSecurities Act. Yes o  No x

 

Indicate by check mark ifthe registrant is not required to file reports pursuant to Section 13 orSection 15(d) of the Act. Yes o  No x

 

Indicateby check mark whether the registrant (1) has filed all reports required tobe filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that theregistrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days. Yes o   No x

 

Indicateby check mark whether the registrant has submitted electronically and posted onits corporate Web site, if any, every Interactive Data File required to besubmitted and posted pursuant to Rule 405 of Regulation S-T (§232.405of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit and post suchfiles). Yes o  No o

 

Indicateby check mark if disclosure of delinquent filers pursuant to Item 405 ofRegulation S-K (Section 229.405 of this chapter) is not containedherein, and will not be contained, to the best of registrant’s knowledge, indefinitive proxy or information statements incorporated by reference in Part IIIof this Form 10-K or any amendment to this Form 10-K. o

 

Indicateby check mark whether the registrant is a large accelerated filer, anaccelerated filer, a non-accelerated filer, or a smaller reporting company. Seedefinition of “large accelerated filer,” “accelerated filer” and “smallerreporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

| Large accelerated filer x                                       |   | Accelerated filer o              |
|--------------------------------------------------------------------------------|--------|--------------------------------------------|
| Non-accelerated filer o(Do not check if a smaller reporting company) |   | Smaller reporting company o |

 

Indicateby check mark whether the registrant is a shell company (as defined in ExchangeAct Rule 12b-2). Yes o   No x

 

Theaggregate market value of the common stock of the registrant as of June 30,2009 held by non-affiliates was $645,730,218.

 

Thenumber of shares outstanding of the registrant’s common stock was 142,951,264as of February 16, 2010.

 

**DOCUMENTS INCORPORATED BY REFERENCE**

 

Portions of the registrant’sDefinitive Proxy Statement to be filed with the Securities and ExchangeCommission (the “Commission”) pursuant to Regulation 14A in connectionwith the 2010 Annual Meeting of Stockholders to be held on April 29, 2010are incorporated herein by reference into Part III of this Annual Report.Such Definitive Proxy Statement will be filed with the Commission not laterthan 120 days after December 31, 2009.

 

 

 

----

 

**EXPLANATORYNOTE**

 

In accordance withRule 12b-15 under the Securities and Exchange Act of 1934, as amended, weare filing this abbreviated Amendment No.1 to the Annual Report on Form 10-K(this “Form 10-K/A”) of Amylin Pharmaceuticals, Inc. (the “Registrant”)for the year ended December 31, 2009 (the “2009 Form 10-K”), solelyto amend the coversheet to the 2009 Form 10-K.

 

In addition, inaccordance with applicable Securities and Exchange Commission rules,Item 15(b) of Part IV of the 2009 Form 10-K has beenamended to include currently-dated certifications from our President and ChiefExecutive Officer, who is our principal executive officer, and our Senior VicePresident, Finance and Chief Financial Officer, who is our principal accountingand financial officer, as Exhibits 31.3 and 31.4.

 

Except foramending the coversheet to the 2009 Form 10-K and Item 15(b) of Part IVof the Form 10-K as indicated above, this Form 10-K/A does notrevise, update, or in any way affect any information or disclosure contained inthe 2009 Form 10-K and we have not updated the disclosures containedherein to reflect events that occurred at a later date.

 

**PART IV**

 

**Item 15.    *Exhibits and Financial Statement Schedules***

 

**(b)**

 

**Exhibits**

 
| **Exhibit********Footnote** | ** ** | **Exhibit********Number** | ** ** | ** **                                                                                                                                                                         |
|-----------------------------|------------|---------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1)                         |       | 3.1                       |       | Amended  and Restated Certificate of Incorporation of the Registrant.                                                                                                              |
| (4)                         |       | 3.2                       |       | Fourth  Amended and Restated Bylaws of the Registrant.                                                                                                                             |
| (9)                         |       | 3.3                       |       | Certificate  of Amendment of Amended and Restated Certificate of Incorporation of the  Registrant.                                                                                 |
| (29)                        |       | 3.4                       |       | Certificate  of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.                                                                                  |
|                        |       | 4.1                       |       | Reference  is made to Exhibits 3.1 - 3.4.                                                                                                                           |
| (13)(2)                     |       | 4.2                       |       | Registration  Rights Agreement dated September 19, 2002, between the Registrant and  Eli Lilly and Company.                                                                   |
| (12)                        |       | 4.3                       |       | Rights  Agreement dated June 17, 2002, between the Registrant and American Stock  Transfer & Trust Company.                                                          |
| (12)                        |       | 4.4                       |       | Certificate  of Designation of Series A Junior Participating Preferred Stock.                                                                                                 |
| (18)                        |       | 4.5                       |       | First  Amendment to Rights Agreement dated December 13, 2002, between the  Registrant and American Stock Transfer & Trust Company.                                   |
| (7)                         |       | 4.6                       |       | Indenture,  dated as of April 6, 2004, between Registrant and J.P. Morgan Trust  Company, National Association (as Trustee).                                                  |
| (7)                         |       | 4.7                       |       | Form of  2.50% Convertible Senior Note due 2011.                                                                                                                              |
| (28)                        |       | 4.8                       |       | Indenture,  dated as of June 8, 2007, between Registrant and The Bank of New York  Trust Company, N.A. (as Trustee).                                                          |
| (28)                        |       | 4.9                       |       | Registration  Rights Agreement, dated as of June 8, 2007, among Registrant, Goldman  Sachs & Co. and Morgan Stanley & Co.  Incorporated.          |
| (1)                         |       | 10.1                      |       | Form of  Indemnity Agreement entered into between the Registrant and its directors and  officers.†                                                                       |
| (10)                        |       | 10.2                      |       | Registrant’s  1991 Stock Option Plan, as amended.†                                                                                                                       |
| (3)                         |       | 10.3                      |       | Form of  Incentive Stock Option Agreement under the 1991 Stock Option Plan.†                                                                                             |
| (1)                         |       | 10.4                      |       | Form of  Supplemental Stock Option Agreement under the 1991 Stock Option Plan.†                                                                                          |
| (1)                         |       | 10.5                      |       | Form of  Supplemental Stock Option Agreement not granted under the 1991 Stock Option  Plan with related schedule.†                                                       |
| (34)                        |       | 10.6                      |       | Registrant’s  Amended and Restated 2001Employee Stock Purchase Plan.†                                                                                                    |
| (33)                        |       | 10.7                      |       | Registrant’s  Non-Employee Directors’ Stock Option Plan (the “Directors’ Plan”).†                                                                    |
| (5)(2)                      |       | 10.8                      |       | Patent  and Technology License Agreement, Consulting Agreement and Nonstatutory Stock  Option Agreement dated October 1, 1996, between the Registrant and  Dr. John Eng. |
| (6)                         |       | 10.9                      |       | Registrant’s  Directors’ Deferred Compensation Plan.†                                                                                                               |
| (36)                        |       | 10.10                     |       | Registrant’s  Directors’ Plan Stock Option Agreement, as amended.†                                                                                                  |
| (8)                         |       | 10.11                     |       | Special  Form of Incentive Stock Option Agreement the 1991 Stock Option Plan of  the Registrant.†                                                                        |

 

2

----

 
| **Exhibit  Footnote** | ** ** | **Exhibit  Number** | ** ** | ** **                                                                                                                                                                      |
|-----------------------|------------|---------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (11)(2)               |       | 10.12               |       | Development  and License Agreement dated May 15, 2000, between the Registrant and  Alkermes Controlled Therapeutics II, Inc.                                          |
| (32)                  |       | 10.13               |       | Registrant’s  Amended and Restated Officer Change in Control Severance Benefit Plan.†                                                                                 |
| (24)                  |       | 10.14               |       | Registrant’s  Amended and Restated 2001 Equity Incentive Plan.†                                                                                                       |
| (13)(2)               |       | 10.15               |       | Collaboration  Agreement dated September 19, 2002, between the Registrant and Eli Lilly  and Company.                                                                      |
| (13)(2)               |       | 10.16               |       | U.S.  Co-Promotion Agreement dated September 19, 2002, between the Registrant  and Eli Lilly and Company.                                                                  |
| (13)                  |       | 10.17               |       | Milestone  Conversion Agreement dated September 19, 2002, between the Registrant  and Eli Lilly and Company.                                                               |
| (16)(2)               |       | 10.18               |       | Device  Development and Manufacturing Agreement dated July 1, 2003, between  Registrant and Eli Lilly and Company.                                                         |
| (15)                  |       | 10.19               |       | Form of  Registrant’s 2001 Equity Incentive Plan Officer Stock Option Agreement, as  amended.†                                                                   |
| (15)                  |       | 10.20               |       | Form of  Registrant’s 2001 Equity Incentive Plan Stock Option Agreement, as amended.†                                                                            |
| (17)(2)               |       | 10.21               |       | Manufacturing  Agreement dated May 12, 2003, between Registrant and UCB S.A.                                                                                          |
| (19)(2)               |       | 10.22               |       | Exenatide  Manufacturing Agreement dated October 1, 2003, between Registrant and  Mallinckrodt Inc.                                                                   |
| (19)(2)               |       | 10.23               |       | Commercial  Supply Agreement for Exenatide dated December 23, 2003, between  Registrant and Bachem, Inc.                                                              |
| (20)(2)               |       | 10.24               |       | Commercial  Supply Agreement dated February 14, 2005 between Registrant and Baxter  Pharmaceutical Solutions LLC.                                                     |
| (20)(2)               |       | 10.25               |       | Commercial  Supply Agreement dated March 2, 2005 between Registrant and Baxter  Pharmaceutical Solutions LLC.                                                         |
| (36)                  |       | 10.26               |       | Summary  Description of Registrant’s Named Executive Officer Oral At-Will Employment  Agreements.†                                                                    |
| (21)                  |       | 10.27               |       | Description  of Registrant’s Executive Cash Bonus Plan.†                                                                                                              |
| (23)(2)               |       | 10.28               |       | Amendment  to Development and License Agreement dated October 24, 2005, between  Registrant and Alkermes Controlled Therapeutics II.                                       |
| (22)(2)               |       | 10.29               |       | Commercial  Supply Agreement dated June 28, 2005, between Registrant and  Bachem, Inc.                                                                                |
| (25)(2)               |       | 10.30               |       | Commercial  Supply Agreement dated October 12, 2006 between Registrant and Wockhardt  UK (Holdings) Ltd.                                                              |
| (25)(2)               |       | 10.31               |       | Amendment  to Collaboration Agreement dated October 31, 2006 between Registrant and  Eli Lilly and Company.                                                                |
| (26)                  |       | 10.32               |       | Employment  Agreement, dated March 7, 2007, by and between Registrant and Daniel M.  Bradbury.†                                                                       |
| (30)                  |       | 10.33               |       | Registrant’s  2001 Non-Qualified Deferred Compensation Plan.†                                                                                                         |
| (30)                  |       | 10.34               |       | Credit  Agreement, dated as of December 21, 2007, among Registrant, The Bank of  America, N.A. (as Administrative Agent) and the other lenders set forth  therein.         |
| (31)                  |       | 10.35               |       | First  Amendment to Exenatide Manufacturing Agreement dated January 6, 2006,  between Registrant and Mallinckrodt Inc.                                                |
| (31)(2)               |       | 10.36               |       | Amended  and Restated Commercial Supply Agreement dated April 1, 2008, between  Registrant and Wockhardt UK (Holdings) Ltd.                                           |
| (31)(2)               |       | 10.37               |       | Addendum  to U.S. Co-Promotion Agreement dated May 8, 2008, between Registrant and  Eli Lilly and Company.                                                                 |
| (31)(2)               |       | 10.38               |       | Third  Amendment to Supply Agreement dated January 1, 2008, between Registrant  and Mallinckrodt Inc.                                                                 |
| (4)                   |       | 10.39               |       | Amendment  to Employment Agreement dated December 3, 2008, between Registrant and  Daniel M. Bradbury.†                                                               |
| (32)(2)               |       | 10.40               |       | Exenatide  Once Weekly Supply Agreement, dated October 16, 2008, between Registrant  and Eli Lilly and Company.                                                            |
| (32)                  |       | 10.41               |       | Loan  Agreement dated October 16, 2008, between Registrant and Eli Lilly and  Company.                                                                                     |
| (32)                  |       | 10.42               |       | First  Amendment to Credit Agreement, dated October 27, 2008, among Registrant,  the Bank of America, N.A. (as Administrative Agent) and other lenders set  forth therein. |
| (32)(2)               |       | 10.43               |       | Amendment  to Commercial Supply Agreement dated December 8, 2008, between  Registrant and Baxter Pharmaceutical Solutions LLC.                                        |
| (32)(2)               |       | 10.44               |       | Amendment  to the Amended and Restated Commercial Supply Agreement dated  January 23, 2009, between Registrant and Wockhardt UK  (Holdings) Ltd.                      |
| (33)                  |       | 10.45               |       | Amendment,  dated April 9, 2009, to Collaboration Agreement between Registrant and  Eli Lilly and Company.                                                                 |
| (34)                  |       | 10.46               |       | Registrant’s  2009 Equity Incentive Plan.†                                                                                                                            |

 

3

----

 
| **Exhibit  Footnote** | ** ** | **Exhibit  Number** | ** ** | ** **                                                                                                                                                                  |
|-----------------------|------------|---------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (34)                  |       | 10.47               |       | Registrant’s  2009 Equity Incentive Plan Officer Stock Option Agreement.†                                                                                         |
| (34)                  |       | 10.48               |       | Registrant’s  2009 Equity Incentive Plan Stock Option Agreement.†                                                                                                 |
| (35)(2)               |       | 10.49               |       | Cost  Allocation Agreement, dated May 4, 2009, between Registrant and Eli  Lilly and Company.                                                                          |
| (35)                  |       | 10.50               |       | Second  Amendment, dated May 6, 2009, to Credit Agreement among Registrant, Bank  of America N.A., as Administrative Agent, and certain lenders thereto.               |
| (35)(2)               |       | 10.51               |       | Exenatide  Once Weekly Supply Agreement, dated May 11, 2009, between Registrant and  Eli Lilly and Company.                                                            |
| (36)                  |       | 10.52               |       | License,  Development and Commercialization Agreement, dated October 30, 2009,  between Registrant and Takeda Pharmaceutical Company Limited.*                         |
| (36)                  |       | 10.53               |       | Side  Letter Agreement, dated October 30, 2009, between Registrant and Takeda  Pharmaceutical Company Limited.*                                                        |
| (36)                  |       | 10.54               |       | Third  Amendment, dated December 18, 2009, to Credit Agreement among  Registrant, Bank of America N.A., as Administrative Agent, and certain  lenders thereto.         |
| (36)                  |       | 18                  |       | Letter  from Independent Registered Public Accounting Firm related to change in  accounting principle.                                                                      |
| (36)                  |       | 21.1                |       | Subsidiaries  of Registrant.                                                                                                                                                |
| (36)                  |       | 23.1                |       | Consent  of Independent Registered Public Accounting Firm.                                                                                                                  |
| (36)                  |       | 24.1                |       | Power  of Attorney. Reference is made to page 71.                                                                                                                      |
| (36)                  |       | 31.1                |       | Certification  of Principal Financial Officer pursuant to Rule 13a-14(a) and  Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.        |
| (36)                  |       | 31.2                |       | Certification  of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of  the Securities Exchange Act of 1934, as amended.        |
|                  |       | 31.3                |       | Certification  of Principal Executive Officer pursuant to Rule 13a-14(a) and  Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.        |
|                  |       | 31.4                |       | Certification  of Principal Executive Officer pursuant to Rule 13a-14(a) and  Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.        |
| (36)                  |       | 32.1                |       | Certifications  Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906  of the Public Company Accounting Reform and Investor Protection Act of 2002. |

 

----

*† *Indicates management or compensatory plan or arrangement required to beidentified pursuant to Item 15(c).

 

** *Confidentialtreatment has been requested with respect to certain portions of this exhibit.Omitted portions have been filed separately with the Securities and ExchangeCommission.

 

*(1) *Filed as an exhibit to theRegistrant’s Registration Statement on Form S-1 (No. 33-44195) oramendments thereto and incorporated herein by reference.

 

*(2) *Confidential Treatment hasbeen granted by the Securities and Exchange Commission with respect to portionsof this agreement.

 

*(3) *Filed as an exhibit to theRegistrant’s Annual Report on Form 10-K for the fiscal year ended December 31,1995, and incorporated herein by reference.

 

*(4) *Filed as an exhibit on Form 8-Kdated December 8, 2008, and incorporated herein by reference.

 

*(5) *Filed as an exhibit to theRegistrant’s Quarterly Report on Form 10-Q for the quarter ended September 30,1996, and incorporated herein by reference.

 

*(6) *Filed as an exhibit to theRegistrant’s Registration Statement on Form S-8 (No. 333-61660) oramendments thereto and incorporated herein by reference.

 

*(7) *Filed as an exhibit to theRegistrant’s Quarterly Report on Form 10-Q for the quarter ended March 31,2004, and incorporated herein by reference.

 

*(8) *Filed as an exhibit to theRegistrant’s Quarterly Report on Form 10-Q for the quarter ended March 31,1998, and incorporated herein by reference.

 

*(9) *Filed as an exhibit to theRegistrant’s Quarterly Report on Form 10-Q for the quarter ended September 30,2001, and incorporated herein by reference.

 

*(10) *Filed as an exhibit to theRegistrant’s Quarterly Report on Form 10-Q for the quarter ended September 30,1999, and incorporated herein by reference.

 

4

----

 

*(11)*Filed as an exhibit to the Registrant’sQuarterly Report on Form 10-Q for the quarter ended June 30, 2000,and incorporated herein by reference.

 

*(12)*Filed as an exhibit on Form 8-K dated June 18,2002, and incorporated herein by reference.

 

*(13)*Filed as an exhibit on Form 8-K dated October 3,2002, and incorporated herein by reference.

 

*(14)*Filed as an exhibit to Registrant’s AnnualReport on Form 10-K for the fiscal year ended December 31, 2001, andincorporated herein by reference.

 

*(15)*Filed as an exhibit to Registrant’s QuarterlyReport on Form 10-Q for the quarter ended September 30, 2003, andincorporated herein by reference.

 

*(16)*Filed as an exhibit to Amendment 1 toRegistrant’s Quarterly Report on Form 10-Q/A for the quarter ended June 30,2003, and incorporated herein by reference.

 

*(17)*Filed as an exhibit to Amendment 1 toRegistrant’s Quarterly Report on Form 10-Q/A for the quarter ended September 30,2003, and incorporated herein by reference.

 

*(18)*Filed as an exhibit to Registrant’s AnnualReport on Form 10-K for the fiscal year ended December 31, 2002, andincorporated herein by reference.

 

*(19)*Filed as an exhibit to Amendment 1 toRegistrant’s Annual Report on Form 10-K/A for the fiscal year ended December 31,2003, and incorporated herein by reference.

 

*(20)*Filed as an exhibit to Registrant’s AnnualReport on Form 10-K for the fiscal year ended December 31, 2004, andincorporated herein by reference.

 

*(21)*Filed on Form 8-K dated February 5,2010, and incorporated herein by reference.

 

*(22)*Filed as an exhibit to Registrant’s QuarterlyReport on Form 10-Q for the quarter ended June 30, 2005, andincorporated herein by reference.

 

*(23)*Filed as an exhibit to Registrant’s Annual Reporton Form 10-K for the fiscal year ended December 31, 2005, andincorporated herein by reference.

 

*(24)*Filed as an exhibit on Form 8-K dated May 30,2008 and incorporated herein by reference.

 

*(25)*Filed as an exhibit to Registrant’s AnnualReport on Form 10-K for the fiscal year ended December 31, 2006, andincorporated herein by reference.

 

*(26)*Filed as an exhibit to Registrant’s QuarterlyReport on Form 10-Q for the quarter ended March 31, 2007, andincorporated herein by reference.

 

*(27)*Filed as an exhibit on Form 8-K dated May 29,2007, and incorporated herein by reference.

 

*(28)*Filed as an exhibit on Form 8-K dated June 8,2007, and incorporated herein by reference.

 

*(29)*Filed as an exhibit to Registrant’s QuarterlyReport on Form 10-Q for the quarter ended June 30, 2007, andincorporated herein by reference.

 

*(30)*Filed as an exhibit to Registrant’s Annualreport on Form 10-K for the fiscal year ended December 31, 2007, andincorporated herein by reference.

 

*(31)*Filed as an exhibit to Registrant’s QuarterlyReport on Form 10-Q for the quarter ended June 30, 2008, andincorporated herein by reference.

 

*(32)*Filed as an exhibit to Registrant’s AnnualReport on Form 10-K for the fiscal year ended December 31, 2008, andincorporated herein by reference.

 

*(33)*Filed as an exhibit to Registrant’s Quarterlyreport on form 10-Q for the quarter ended March 31, 2009, andincorporated herein by reference.

 

*(34)*Filed as an exhibit on Form 8-K dated June 10,2009, and incorporated herein by reference.

 

*(35)*Filed as an exhibit to Registrant’s QuarterlyReport on Form 10-Q for the quarter ended June 30, 2009, andincorporated herein by reference.

 

*(36)*Filed as an exhibit to Registrant’s AnnualReport on Form 10-K for the year ended December 31, 2009, andincorporated herein by reference.

 

5

----

 

**SIGNATURES**

 

Pursuant to therequirements of Section 13 or 15(d) of the Securities Exchange Act of1934, the Registrant has duly caused this Form 10-K/A to be signed on itsbehalf by the undersigned, thereunto duly authorized.

 
|                       | AMYLIN  PHARMACEUTICALS, INC. |
|----------------------------|------------------------------------|
| Date:  April 19, 2010 |                               |   |
|                       |                               | * * |
|                       | By:                                | /s/ Daniel  M. Bradbury |
|                       |                               | Daniel M. Bradbury, |
|                       |                               | *President  and Chief Executive Officer* |

 

6

----